New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:53 EDTCRMECardiome's Brinavess shows positive results in cardiological study
Cardiome announced that an independent, investigator-led investigation demonstrated real-world cardioversion experience with Brinavess RINAVESS (vernakalant IV) in patients who developed post-cardiac surgery atrial fibrillation. This was a prospective, non-randomised, single-arm study in 50 patients. The primary outcome was the conversion of atrial fibrillation to sinus rhythm 90 minutes post-Brinavess RINAVESS infusion. Brinavess was successful in cardioverting 74% of the patients.
News For CRME From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 28, 2015
16:47 EDTCRMECardiome announces approximately $15M bought deal financing
Cardiome announced that it has entered into an agreement with a syndicate of underwriters led by Cormark Securities, acting as sole bookrunner and co-lead underwriter and Canaccord Genuity Corp., acting as co-lead underwriter and including Brean Capital LLC and Laurentian Bank Securities, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 1.875M common shares from the treasury of the Company at a price of $8.00 per share, for gross proceeds of approximately $15M. The Offering is expected to close on or about August 13. Completion of the Offering is subject to, and conditional upon, the receipt of all necessary approvals, including approval of the Toronto Stock Exchange and the NASDAQ.
16:27 EDTCRMECardiome trading halted, news pending
Subscribe for More Information
July 24, 2015
08:05 EDTCRMECardiome partner Eddingpharm to initiate Brinavess Phase I study in China
Subscribe for More Information
July 22, 2015
08:06 EDTCRMECardiome submits supplemental NDS for Aggrastat in Canada
Cardiome has submitted a Supplemental New Drug Submission to Health Canada's Therapeutic Products Directorate for Aggrastat. The sNDS includes data to support High Dose Bolus administration of Aggrastat and an indication expansion for the reduction of major cardiovascular events in patients with acute myocardial infarction intended for primary PCI. Aggrastat, in combination with heparin and ASA is currently indicated in Canada for the management of patients with unstable angina or non-Q-wave myocardial infarction

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use